The FDA Expands Collaboration With CN Bio to Investigate Lung-on-a-chip Model for Inhaled Drug Evaluation Applications Follows success of initial project demonstrating the advanced performance of the Company's liver-on-a-chip platform CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the U.S. Food and Drug Administration (FDA) has extended their research collaboration, for a further three years. The scope of the research carried out with the FDA's Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio's lung-on-a-chip using the PhysioMimix MPS platform, to appraise the system's use for the evaluation of inhaled drug products and assessing additional applications for CN Bio's liver model.